Galmed Pharmaceuticals annual depreciation and amortization
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Galmed Pharmaceuticals Depreciation & Amortization Growth & History (GLMD)
Galmed Pharmaceuticals's depreciation and amortization was $0 for fiscal 2025.
View full Galmed Pharmaceuticals company overviewGalmed Pharmaceuticals annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$83,000 | — |
| 2024 | 2024-12-31 | $83,000 | $52,000 | +167.74% |
| 2023 | 2023-12-31 | $31,000 | −$4,000 | −11.43% |
| 2022 | 2022-12-31 | $35,000 | −$7,000 | −16.67% |
| 2021 | 2021-12-31 | $42,000 | $3,000 | +7.69% |
| 2020 | 2020-12-31 | $39,000 | $4,000 | +11.43% |
| 2019 | 2019-12-31 | $35,000 | −$352,000 | −90.96% |
| 2018 | 2018-12-31 | $387,000 | $148,000 | +61.92% |
| 2017 | 2017-12-31 | $239,000 | $70,000 | +41.42% |
| 2016 | 2016-12-31 | $169,000 | $119,000 | +238.00% |
| 2015 | 2015-12-31 | $50,000 | $41,000 | +455.56% |
| 2014 | 2014-12-31 | $9,000 | $5,000 | +125.00% |
| 2013 | 2013-12-31 | $4,000 | −$1,000 | −20.00% |
| 2012 | 2012-12-31 | $5,000 | — | — |
Galmed Pharmaceuticals quarterly depreciation and amortization
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $0 | $0 | — |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | — | — |
| Q1 2025 | 2025-03-31 | $0 | — | — |
| Q4 2024 | 2024-12-31 | $0 | — | — |
| Q3 2024 | 2024-09-30 | $0 | — | — |
Galmed Pharmaceuticals depreciation and amortization trends
Over the last five fiscal years, Galmed Pharmaceuticals's depreciation and amortization decreased from $39,000 to $0, a change of −$39,000. The latest reported quarter, Q4 2025, shows $0.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Galmed Pharmaceuticals source filings ↗